Abeona Therapeutics (ABEO) EBT (2011 - 2026)

Abeona Therapeutics' EBT history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, EBT fell 41.93% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $66.2 million (up 249.91% YoY), while the FY2025 annual figure was $71.3 million, up 211.84% from the prior year.
• EBT for Q1 2026 stood at -$17.1 million, up from -$20.7 million in the prior quarter.
• The five-year high for EBT was $124.3 million in Q2 2025, with the low at -$32.1 million in Q1 2022.
• The 5-year median for EBT is -$13.3 million (2023), against an average of -$7.5 million.
• The sharpest annual moves came in 2024 and 2025: EBT tumbled 138.26% in 2024, then soared 1578.98% in 2025.
• Abeona Therapeutics' EBT stood at -$13.1 million in 2022, then dropped by 1.56% to -$13.3 million in 2023, then soared by 30.22% to -$9.3 million in 2024, then tumbled by 122.48% to -$20.7 million in 2025, then grew by 17.42% to -$17.1 million in 2026.
• Business Quant data shows ABEO's EBT at -$17.1 million in Q1 2026, -$20.7 million in Q4 2025, and -$20.4 million in Q3 2025.